Metropolis Healthcare Limited has informed the Exchange regarding 'Business update for Q1FY26'.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported approximately 23% year-on-year revenue growth for Q1FY26 on a consolidated basis, boosted by the consolidation of Core Diagnostics, Scientific Pathology, Agra and Dr. Ahuja's Pathology & Imaging Center (DAPIC). Excluding these acquisitions, organic revenue growth was around 13%, driven by higher patient and test volumes, a better product mix and improved realizations. B2C revenues grew about 15%, while TruHealth Wellness and Specialty segments grew roughly 20% and 15% respectively. Specialty revenues surged 35%+ YoY, largely due to Core's high-end oncology testing. Core Diagnostics shifted from breakeven in Q4FY25 to positive single-digit margins, though consolidated EBITDA margin dipped slightly due to Core's inclusion. The company remains debt-free and views the Q4FY25 industry slowdown as seasonal rather than structural.
Strong double-digit organic growth and improving acquisition margins suggest a healthy operating quarter for shareholders, though slight consolidated margin pressure from the Core integration is a minor watchpoint. Overall, the update points to steady business momentum without any change in competitive positioning.